nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial

por Tabernero, Josep, Kunzmann, Volker, Scheithauer, Werner, Reni, Michele, Shiansong Li, Jack, Ferrara, Stefano, Djazouli, Kamel
Publicado 2017

Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine: An Exploratory Analysis From a Phase 3 Study

por Kunzmann, Volker, Ramanathan, Ramesh K., Goldstein, David, Liu, Helen, Ferrara, Stefano, Lu, Brian, Renschler, Markus F., Von Hoff, Daniel D.
Publicado 2017

Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

por Tempero, Margaret A., Pelzer, Uwe, O'Reilly, Eileen M., Winter, Jordan, Oh, Do-Youn, Li, Chung-Pin, Tortora, Giampaolo, Chang, Heung-Moon, Lopez, Charles D., Bekaii-Saab, Tanios, Ko, Andrew H., Santoro, Armando, Park, Joon Oh, Noel, Marcus S., Frassineti, Giovanni Luca, Shan, Yan-Shen, Dean, Andrew, Riess, Hanno, Van Cutsem, Eric, Berlin, Jordan, Philip, Philip, Moore, Malcolm, Goldstein, David, Tabernero, Josep, Li, Mingyu, Ferrara, Stefano, Le Bruchec, Yvan, Zhang, George, Lu, Brian, Biankin, Andrew V., Reni, Michele
Publicado 2023